Member Info for Toukankahmoon

F3rd, you know that BV can never bring themselves to agree with anything I post. Most of us, including CC, know that excellent P1b results will be the key that opens the door to licensing deals and a proper re rate, not the poxy little 10p jumps that people are WOWing about now.

Clutching at straws. The rapid descent from 280 was WOW. or something similar.

And sorry, what was the SP this time last year?🤡🤡🤡

. . . it’s a resistance line until you get above it, then it’s a support line🤣

. . . bit of FOMO ahead of P1b results 👍

I’m delighted we are moving up, but it’s hardly “wow” is it🤣

11.1p sounds ok without further news

. . . starting to look like a classic head and shoulders to me. So I am expecting a fall back next week. But I am just a simple soul. Also I cannot see the pivotal P1b results getting published before December. But as always just my view based on history and what CC is saying. Having said that I also don’t see much downside so buying now is probably a good call for the longer term. But that’s been true for weeks now.

“Success there could move the dial."

Did Windrum write this?????

But sadly it reflects what the potential investors think of Avacta.

Fingers crossed that it drops before Christmas 🚀🚀🚀

Hooray. Excellent factual thread with no fud or ramping bias.

If only all the posts/threads on here could be this friendly and rational.

That would be nice. To my recollection that was their target for end 2025, made 6 months or so ago after CC laid out her roadmap for the year. Have they recently reiterated this?

. . . spot on in my opinion. Excellent unambiguous P1b data (still due this year????) will be the key to unlock a deal and precipitate a massive rerate IMHO.

I am invested in HEMO and believe over time my investment will come good. But I am interested in folk pointing out risks and the possible outcomes which I might not have thought about.

What hacks me off is the attitude of those who cannot entertain any notion of risks and therefore abuse and slag off anyone who dares bring them into the discussion. It is so short sighted in addition to being ignorant/rude.

Just saying

For a friend

So sad to see so many falling unconditionally in love with a share. This BB would be far more useful if it encouraged grown up debate about the potential risks and rewards. But most on here don’t seem to want any sort of discussion. They just want an echo chamber that heaps praise on the subject of their admiration. Not a good investment strategy in my opinion.

. . . good news for those of us in HEMO.

“personalised medicine and our ability to manipulate the cells and the genes of the individual”

. . Pom Pom (singular). I’m waving your other one 🤣🤣🤣

Https://avacta.com/wp-content/uploads/2024/06/Targeting-the-tumor-microenvironment-June-2024.pdf

Slide 22

CC’s “favourite “ slide - June 2024 targeting the TME

how can you watch cc speak and think that there will be a bidding war, unless you mean in terms of licence terms.

thorn tnbc is not high fap. in fact it nearly went under the radar until they picked up that a lower fap tumour still cleaved ava600. and before you start an argument, i did not say tnbc was low fap., just not high fap. cc describes it well in a video somewhere. and also the discussion with a us doctor whose tnbc patients were responding well to a ****tail containing doxorubicin but then dying of the side effects.

Economist

Please don’t join the ranks of peeps on here who just write what they think or want to believe.

This has been well discussed before. Folks in US can already buy shares - via $AVCTF.

A dual listing is something entirely different and requires Avacta to place a proportion of their capital in a new listing on NASDAQ. For it to achieve any effect it would need to be a large proportion.

Now please DYOR before posting rubbish.

Cfds

What is your average purchase price and what do you think BP would offer right now to take us over? £1 £2?

The last thing we need right now is a takeover.

And the other b*ll*cks about a NASDAQ listing also makes me spit feathers. It isn’t called a “dual listing” for nothing. To make any sense the capital on NASDAQ would have to be equal to that held on AIM. So instant massive dilution. Yes I know. There are other ways - reverse takeover of a shell company etc. but these are complicated and still result in some dilution. Also it’s no longer clear that a NASDAQ listing is the be all and end all.

We desperately need excellent P1b data to clinch a lucrative licensing deal. Anything else and we get scr*wed.